I would strongly suggest you send some feedback with the company and start some dialog. I have recently and have been exchanging some e-mails with them. They are very responsive and articulate. I inquired on the different dosing levels and I think they would like to do more human studies on dosage levels, frequencies, etc. They are limited with resources, etc. Obviously the FX trial could have potentially opened some doors on partnerships, etc., to advance this more quickly.
News 
Market Data 
Discover 
